GPP
Great Point Partners Portfolio holdings
AUM
$240M
1-Year Est. Return
106.75%
1 Year Est. Return
+106.75%
AUM
$154M
AUM Growth
-$30.2M
(-16%)
Holding
37
Top Buys
| 1 | +$9.88M | |
| 2 | +$9.81M | |
| 3 | +$7.52M | |
| 4 |
AKRO
Akero Therapeutics
AKRO
|
+$5.54M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$4.98M |
Top Sells
| 1 | +$10.9M | |
| 2 | +$10.1M | |
| 3 | +$9.98M | |
| 4 |
KalVista Pharmaceuticals
KALV
|
+$7.81M |
| 5 |
Ascendis Pharma
ASND
|
+$7.79M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$13B
| $19.8M | 12.84% |
500,000
+250,000
|
|
||
2
Rezolute
RZLT
$326M
| $13.5M | 8.8% |
3,033,462
+2,200,420
|
|
||
3
Amylyx Pharmaceuticals
AMLX
$1.73B
| $12.8M | 8.34% |
2,000,000
+188,004
|
|
||
4
Legend Biotech
LEGN
$3.51B
| $12.4M | 8.08% |
350,000
+211,760
|
|
||
|
ABVX
5
Abivax
ABVX
$9.58B
| $9.88M | 6.42% |
1,291,617
-346,494
|
|
||
6
Neurogene
NGNE
$284M
| $7.26M | 4.72% |
485,859
+14,895
|
|
||
7
Akebia Therapeutics
AKBA
$361M
| $7.23M | 4.7% |
1,985,915
-2,987,925
|
|
||
8
Evolus
EOLS
$319M
| $6.63M | 4.31% |
720,118
-224,625
|
|
||
9
Arcellx
ACLX
$3.91B
| $6.58M | 4.28% |
100,000
+55,000
|
|
||
10
Xenon Pharmaceuticals
XENE
$3.23B
| $6.26M | 4.07% |
200,000
-45,272
|
|
||
|
AKRO
11
DELISTED
Akero Therapeutics
AKRO
| $5.54M | 3.6% |
+103,848
|
|
||
|
JBIO
12
Jade Biosciences
JBIO
$804M
| $4.98M | 3.24% |
+498,054
|
|
||
13
Cytokinetics
CYTK
$7.75B
| $4.96M | 3.22% |
150,000
-220,000
|
|
||
14
Immunovant
IMVT
$5.24B
| $4.19M | 2.73% |
262,176
-112,824
|
|
||
15
Unicycive Therapeutics
UNCY
$149M
| $3.8M | 2.47% |
796,558
-301,442
|
|
||
|
16
KalVista Pharmaceuticals
KALV
$810M
| $3.65M | 2.38% |
323,170
-691,197
|
|
||
17
Taysha Gene Therapies
TSHA
$1.28B
| $3.46M | 2.25% |
+1,500,000
|
|
||
|
DBVT
18
DBV Technologies
DBVT
$1.33B
| $3.43M | 2.23% |
+374,679
|
|
||
19
Zura Bio
ZURA
$414M
| $3.33M | 2.16% |
3,170,194
|
|
||
|
UPB
20
Upstream Bio Inc
UPB
$1.62B
| $3.29M | 2.14% |
300,000
|
|
||
21
Context Therapeutics
CNTX
$166M
| $3.07M | 2% |
4,683,711
|
|
||
|
CNTA
22
Centessa Pharmaceuticals
CNTA
$3.74B
| $2.96M | 1.92% |
225,000
+75,298
|
|
||
23
Scholar Rock
SRRK
$4.52B
| $2.18M | 1.42% |
+61,607
|
|
||
24
ProMIS Neurosciences
PMN
$20.3M
| $1.28M | 0.83% |
105,805
|
|
||
25
Pliant Therapeutics
PLRX
$79.9M
| $986K | 0.64% |
850,000
|
|